Drug Trial Radar · NCT07360080
Long-Term Outcomes of Teplizumab in Routine Clinical Care
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Oct 29, 2035
Study completion Oct 29, 2035
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.
Conditions
- Type 1 Diabetes
Interventions
TeplizumabDrug
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from teplizumab infusion start to the onset of Stage 3 T1DTime frame: From start of infusion to maximum of 10 years
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Investigational Site Number: 8400006
Washington D.C., District of Columbia · Recruiting
Investigational Site Number: 8400003
Atlanta, Georgia · Recruiting
Investigational Site Number: 8400004
Atlanta, Georgia · Recruiting
Investigational Site Number: 8400001
New York, New York · Recruiting
Investigational Site Number: 8400002
Syosset, New York · Recruiting
Investigational Site Number: 8400005
Sandy City, Utah · Recruiting
Investigational Site Number: 2760004
Hanover, Germany · Recruiting
Investigational Site Number: 3760003
Petah Tikva, Israel · Recruiting
Investigational Site Number: 3760002
Ramat Gan, Israel · Recruiting
Investigational Site Number: 3760001
Ramat Gan, Israel · Recruiting
Investigational Site Number: 7840001
Abu Dhabi, United Arab Emirates · Recruiting
Investigational Site Number: 7840002
Abu Dhabi, United Arab Emirates · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.